TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xvivo Perfusion AB ( (SE:XVIVO) ) just unveiled an update.
XVIVO Perfusion AB has announced the enrollment of the first patient in the US PRESERVE CAP study for its XVIVO Heart Assist Transport device. This study, approved by the FDA, allows continued clinical use of the device while XVIVO prepares its Pre-Market Approval application. The study’s approval by the Centers for Medicare & Medicaid Services ensures cost recovery, supporting both participating centers and patients. This initiative underscores XVIVO’s commitment to providing life-saving technologies and maintaining continuity of care during the evaluation period.
The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
Founded in 1998, XVIVO is a medical technology company focused on extending the life of major organs to aid transplant teams globally. Headquartered in Gothenburg, Sweden, the company is listed on Nasdaq Stockholm and is dedicated to advancing transplantation medicine.
YTD Price Performance: -56.56%
Average Trading Volume: 122,666
Current Market Cap: SEK6.69B
See more insights into XVIVO stock on TipRanks’ Stock Analysis page.